IP Library Granted Patent US 11,844,720
Granted Patent B2
US 11,844,720 · App. 18/103,768 · Granted Dec 19, 2023

Method and system to reduce the likelihood of dental caries and halitosis

Inventors: Tye Jensen (Telluride, CO); Joseph E. Kovarik (Englewood, CO)
Assignee: Seed Health, Inc.
A61F5/566
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,844,720
App. No.
18/103,768
Granted
Dec 19, 2023
Kind
B2
Abstract

A method to facilitate the growth of desired bacteria in a human's mouth to reduce the likelihood of dental caries and halitosis and other oral diseases, and for inhibiting oral biofilm formation, gingivitis, periodontitis and halitosis via the employment of one or more probiotic bacterial, bioactive flavonoid, and zinc compound compositions effective in providing prevention and treatment options.

Claims (36)

1. A method for reducing the likelihood of developing dental caries and halitosis, comprising:

providing to an oral cavity of an individual subject a first bacterial composition comprising beneficial bacteria adapted to form a biofilm, said beneficial bacteria comprising a bacterium of the genus Rothia , and wherein said bacterial composition does not inhibit growth of a bacterium of species Lactobacillus salivarius;

topically administering to the individual subject a second composition comprising:

an oral probiotic comprising at least two of the following bacteria: Lactobacillus brevis CD2, Streptococcus sanguinis BCC23, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus johnsonii, Bifidobacterium bifidum, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus casei strain Shirota, Lachnospira, Veillonella, Faecalibacterium and Prevotella;

at least one zinc-based compound selected from the group consisting of zinc acetate, zinc chloride, zinc citrate, and zinc sulphate; and

at least one bioactive flavonoid selected from the group consisting of baicalein, naringenin, catechins, quercetin, trans-resveratrol, luteolin, kaempferol, hesperidin, hesperetin, naringin, diosmin, rutin, nobiletin, and tangeretin.

2. The method of claim 1 , wherein the step of topically administering comprises providing said second composition in the form of one of a toothpaste, mouth wash, gargle solution, nose spray, mouth spray, throat spray, chewing gum, hydrogel, oral strip, oral cream, extruded chew and jerky chew.

3. The method of claim 1 , wherein the step of topically administering comprises providing to the individual subject a bioadhesive strip, said strip having a first and second side, said first side having at least one encapsulated feature containing said second composition.

4. The method as set forth in claim 1 , wherein said strip is dissolvable in the individual subject's mouth.

5. The method of claim 1 , further comprising, using a clustered regularly interspaced short palindromic repeats (CRIPSR)-CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Franscisella 1 (Cpf1a) system, selectively killing pathogenic bacteria in the individual subject's oral cavity.

6. The method of claim 1 , wherein said step of providing the first bacterial composition is performed after the individual subject has cleaned their teeth.

7. The method as set forth in claim 1 , wherein said second composition further includes xylitol.

8. The method of claim 1 , wherein said second composition comprises Veillonella bacteria.

9. The method of claim 3 , wherein said strip further comprises breath freshening components.

10. The method as set forth in claim 1 , further comprising providing at least one bacteria that has been modified by employment of a CRISPR-Cas or Cpf1 system to remove a virulence factor selected from the group consisting of gelatinase and hemolysin.

11. The method as set forth in claim 1 , wherein the individual subject is a human.

12. The method as set forth in claim 1 , wherein the individual subject is a canine.

13. The method as set forth in claim 1 , wherein the oral probiotic lowers the pH of the individual subject's oral cavity in an amount sufficient to disrupt the formation of biofilms by pathogenic bacteria.

14. A method for reducing the likelihood of developing dental caries and halitosis, comprising:

providing to an oral cavity of an individual subject a first bacterial composition comprising beneficial bacteria adapted to form a biofilm, said beneficial bacteria comprising a bacterium of the genus Rothia , and wherein said bacterial composition does not inhibit growth of a bacterium of species Lactobacillus salivarius ; said step of providing performed after the individual subject has cleaned their teeth;

topically administering to the individual subject a second composition comprising:

an oral probiotic comprising at least two of the following bacteria: Lactobacillus brevis CD2, Streptococcus sanguinis BCC23, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus johnsonii, Bifidobacterium bifidum, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus casei strain Shirota, Lachnospira, Veillonella, Faecalibacterium and Prevotella;

at least one zinc-based compound selected from the group consisting of zinc acetate, zinc chloride, zinc citrate, and zinc sulphate; and

at least one bioactive flavonoid selected from the group consisting of baicalein, naringenin, catechins, quercetin, trans-resveratrol, Luteolin, kaempferol, hesperidin, hesperetin, naringin, diosmin, rutin, nobiletin, and tangeretin; and

using a clustered regularly interspaced short palindromic repeats (CRIPSR)-CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Franscisella 1 (Cpf1a) system, selectively killing pathogenic bacteria in the individual subject's oral cavity.

15. The method as set forth in claim 14 , wherein said pathogenic bacteria generate volatile sulfur compounds comprising one of methylmercaptan and hydrogen sulfite.

16. The method as set forth in claim 14 , wherein said pathogenic bacteria is Porphyromonas gingivalis.

17. The method as set forth in claim 1 , wherein the individual subject is a human.

18. The method as set forth in claim 1 , wherein the individual subject is a canine.

19. A method for reducing the likelihood of developing dental caries and halitosis, comprising:

providing to an oral cavity of an individual subject a first bacterial composition comprising beneficial bacteria adapted to form a biofilm, said beneficial bacteria comprising a bacterium of the genus Rothia , and wherein said bacterial composition does not inhibit growth of a bacterium of species Lactobacillus salivarius ; said step of providing performed after the individual subject has cleaned their teeth;

topically administering to the individual subject a second composition comprising:

an oral probiotic comprising at least two of the following bacteria: Lactobacillus brevis CD2, Streptococcus sanguinis BCC23, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus casei strain Shirota, and Veillonella;

at least one zinc-based compound selected from the group consisting of zinc acetate, zinc chloride, zinc citrate, and zinc sulphate; and

at least one bioactive flavonoid selected from the group consisting of quercetin, nobiletin, tangeretin; and xylitol.

20. The method of claim 1 , wherein the step of topically administering comprises providing said second composition in the form of one of a toothpaste, mouth wash, gargle solution, nose spray, mouth spray, throat spray, chewing gum, hydrogel, oral strip, and oral cream.

Assignments (2)
SECURITY INTEREST Recorded Jul 21, 2026
From: SEED HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A., AS LENDER
Reel/Frame 076028/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2023
From: JENSEN, TYE; KOVARIK, JOSEPH E.
To: SEED HEALTH, INC.
Reel/Frame 062548/0102 →
Continuity (28)
Continuation In Part 17738771 · May 6, 2022
Continuation In Part 16904056 · Jun 17, 2020
Continuation In Part 15983250 · May 18, 2018
Continuation In Part 15384716 · Dec 20, 2016
Continuation In Part 14752192 · Jun 26, 2015
Continuation In Part 14225503 · Mar 26, 2014
Continuation 13367052 · Feb 6, 2012
Continuation In Part 15270034 · Sep 20, 2016
Continuation In Part 14954074 · Nov 30, 2015
Continuation In Part 14574517 · Dec 18, 2014
Continuation In Part 15228454 · Aug 4, 2016
Continuation In Part 14611458 · Feb 2, 2015
Continuation 14502097 · Sep 30, 2014
Continuation 14307651 · Jun 18, 2014
Continuation In Part 14079054 · Nov 13, 2013
Continuation 13425913 · Mar 21, 2012
Provisional Application 62387405 · Dec 24, 2015
Provisional Application 61439652 · Feb 4, 2011
Provisional Application 61556023 · Nov 4, 2011
Provisional Application 62072476 · Oct 30, 2014
Provisional Application 62053926 · Sep 23, 2014
Provisional Application 62014855 · Jun 20, 2014
Provisional Application 61919297 · Dec 20, 2013
Provisional Application 61467767 · Mar 25, 2011
Provisional Application 62387404 · Dec 24, 2015
Provisional Application 62274550 · Jan 4, 2016
Provisional Application 62275341 · Jan 6, 2016
Related Publication 20230165706A1 · Jun 1, 2023
Cited By (8)
US 12,246,043 US 12,257,272 US 12,279,989 US 12,318,411 US 12,318,414 US 12,329,783 US 12,357,662 US 12,533,312